Bronchitis News and Research RSS Feed - Bronchitis News and Research

Bronchitis is a condition in which the bronchial tubes, the tubes that carry air to your lungs, become inflamed. (For more information on the bronchial tubes and the airways. People who have bronchitis often have a cough that brings up mucus. Mucus is a slimy substance made by the lining of the bronchial tubes. Bronchitis also may cause wheezing (a whistling or squeaky sound when you breathe), chest pain or discomfort, a low fever, and shortness of breath. There are two main types of bronchitis: acute (short term) and chronic (ongoing).
Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza. [More]

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy". [More]
Scientists discover new protein that is involved in cancer, inflammation in lung tissue

Scientists discover new protein that is involved in cancer, inflammation in lung tissue

Scientists from The University of Manchester - part of the Manchester Cancer Research Centre (MCRC) - have discovered a new protein that is involved in cancer and inflammation in lung tissue. [More]

COPD sufferers can reduce risk of being hospitalized by walking 3 kilometers a day

New research in Respirology shows that suffers of Chronic obstructive pulmonary disease (COPD) can reduce their risk of being hospitalized with severe attacks, by maintaining an exercise regime of walking between three to six kilometers a day. [More]
Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients. [More]
Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis Inc. today reported its financial results for the fourth quarter and full year 2013. The company reported revenue of $1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012. Revenue reflected an operational increase of 9%, with foreign currency having a negative impact of 2 percentage points. [More]
Geranium plant extracts prevent HIV-1 from invading human cells

Geranium plant extracts prevent HIV-1 from invading human cells

Extracts of the geranium plant Pelargonium sidoides inactivate human immunodeficiency virus type 1 (HIV-1) and prevent the virus from invading human cells. In the current issue of "PLOS ONE", scientists from the Helmholtz Zentrum München report that these extracts represent a potential new class of anti-HIV-1 agents for the treatment of AIDS. [More]

For many working low-income residents, health law's promise is still unaffordable

Stateline examines the difficulty for many working families to buy insurance while KHN spends time at a California hospital to survey how some without insurance try to afford care. Other news coverage on health law outreach and enrollment looks at narrow networks in some plans and an effort in Connecticut to attract consumers. [More]
Smoking and cancer: an interview with Dr. Lewis Foxhall, VP of Health Policy, University of Texas MD Anderson Cancer Center

Smoking and cancer: an interview with Dr. Lewis Foxhall, VP of Health Policy, University of Texas MD Anderson Cancer Center

The report Smoking and Health: Report of the Advisory Committee to the Surgeon General, identified tobacco as the predominant cause of lung cancer in men. This was the first widely disseminated report based on scientific studies showing the clear link between smoking tobacco and serious health conditions including cancer, chronic lung diseases and heart disease. [More]

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties. [More]
New technique could help researchers unlock the secrets of respiratory syncytial virus

New technique could help researchers unlock the secrets of respiratory syncytial virus

By the time they're two, most children have had respiratory syncytial virus and suffered symptoms no worse than a bad cold. But for some children, especially premature babies and those with underlying health conditions, RSV can lead to pneumonia and bronchitis - which can require hospitalization and have long-term consequences. [More]

Researchers work on breathalyser device to detect early signs of cancer

Researchers at the University of Huddersfield are working on a breathalyser device that will be able to detect very early signs of cancer, making a cure much more likely. [More]
GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%. [More]
Study finds that people with COPD twice likely to develop mild cognitive impairment, memory loss

Study finds that people with COPD twice likely to develop mild cognitive impairment, memory loss

A recent Mayo Clinic study found that people with chronic obstructive pulmonary disease (COPD) are about twice as likely to develop mild cognitive impairment (MCI) -- and chances are that it will include memory loss. The study was recently published in Mayo Clinic Proceedings. [More]
BAL findings boost non-smoking COPD distinction

BAL findings boost non-smoking COPD distinction

Research shows that smoking status, and not airway obstruction, determines the distribution of T cell subsets in bronchoalveolar lavage in patients with chronic obstructive pulmonary disease. [More]

Chronic bronchitis could indicate COPD subtype

Chronic bronchitis is common among patients with chronic obstructive disease and may represent a subtype of the disease that places patients at risk for increased severity and exacerbations, say researchers. [More]
Once-daily prescription medicine for COPD now available throughout the U.S.

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S. [More]

Scientists develop new drug to treat obstructive airway diseases

Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease in two ways at once, according to new research published in The Lancet Respiratory Medicine. [More]
Leukemia drug reverses symptoms of colitis in lab tests

Leukemia drug reverses symptoms of colitis in lab tests

A drug currently on the market to treat leukemia reversed symptoms of colitis in lab tests, according to recently published findings by medical researchers with the University of Alberta. [More]
COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. [More]